drugset / Trial / NCT05552508
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
NaSingle-groupOpen-labelTreatment
Summary
This study will assess the effects of benralizumab on airway dynamics in severe eosinophilic asthma in terms of quantitative computed tomography (CT)-derived measurements of pulmonary structure and function using the Functional Respiratory Imaging (FRI) platform.
Timeline
- Start
- 2022-10-11
- Primary completion
- 2024-07-19
- Completion
- 2024-07-19
Publications
- Carstens DD, De Backer W, Rhodes K, Muchmore P, Lavon BR, Chung SYE, Fogel R, Trudo F, Panettieri R Jr. Impact of benralizumab on airway structure/function in severe eosinophilic asthma. Respir Res. 2026 Jul 15. doi: 10.1186/s12931-026-03742-y. Online ahead of print.
- Genofre E, Carstens D, DeBacker W, Muchmore P, Panettieri RA Jr, Rhodes K, Shih VH, Trudo F. The effects of benralizumab on airway geometry and dynamics in severe eosinophilic asthma: a single-arm study design exploring a functional respiratory imaging approach. Respir Res. 2023 May 3;24(1):121. doi: 10.1186/s12931-023-02415-4.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benralizumab | Monoclonal antibody | 30 mg | Subcutaneous |